Microenvironmental regulation of metastasis

Nature Reviews Cancer

Volumn 9, Issue 4, 2009, Pages 239-252

  Joyce, Johanna A ^a   Pollard, Jeffrey W ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR;

BONE MARROW CELL; CANCER CELL; CANCER INVASION; CANCER LOCALIZATION; CELL ADHESION; CELL INTERACTION; CELL SURVIVAL; CHRONIC INFLAMMATION; HOMEOSTASIS; HUMAN; MESENCHYMAL STEM CELL; METASTASIS; MICROENVIRONMENT; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA CELL; SUPPRESSOR CELL; SYSTEMIC CIRCULATION; TISSUE GROWTH; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD; BONE MARROW; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; MACROPHAGES; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE HYDROLASES; STROMAL CELLS;

EID: 63049104211     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2618     Document Type: Review

References (192)

1. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563-572 (2002). A seminal review summarizing the authors' research on the various routes for metastasis.
2. Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nature Rev. Cancer 6, 449-458 (2006).
3. Kim, J. W. et al. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells. Cancer Lett. 213, 203-212 (2004).
4. MacDonald, I. C., Groom, A. C. & Chambers, A. F. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 24, 885-893 (2002).
5. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
6. Cameron, M. D. et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60, 2541-2546 (2000).
7. Engel, J. et al. The process of metastasisation for breast cancer. Eur. J. Cancer 39, 1794-1806 (2003).
8. Goodison, S. et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin. Cancer Res. 9, 3808-3814 (2003).
9. Brackstone, M., Townson, J. L. & Chambers, A. F. Tumour dormancy in breast cancer: an update. Breast Cancer Res. 9, 208 (2007).
10. Suzuki, M., Mose, E. S., Montel, V. & Tarin, D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am. J. Pathol. 169, 673-681 (2006).
11. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nature Rev. Cancer 7, 834-846 (2007).
12. Holmgren, L., O'Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149-153 (1995). Early concepts of the presence of dormant metastatic cells and the requirement for an angiogenic switch to re-awaken them.
13. Kouros-Mehr, H. et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141-152 (2008).
14. Minn., A. J. et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl Acad. Sci. USA 104, 6740-6745 (2007).
15. Norton, L. & Massague, J. Is cancer a disease of self-seeding? Nature Med. 12, 875-878 (2006).
16. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
17. Nelson, C. M. & Bissell, M. J. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 22, 287-309 (2006).
18. Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72, 3585-3589 (1975). This seminal paper showed that malignant cancer cells could be reprogrammed by the embryonic blastocyst microenvironment, remarkably resulting in normal mosaic mice.
19. Pierce, G. B., Pantazis, C. G., Caldwell, J. E. & Wells, R. S. Specificity of the control of tumor formation by the blastocyst. Cancer Res. 42, 1082-1087 (1982).
20. Dolberg, D. S. & Bissell, M. J. Inability of Rous sarcoma virus to cause sarcomas in the avian embryo. Nature 309, 552-556 (1984).
21. Postovit, L. M., Seftor, E. A., Seftor, R. E. & Hendrix, M. J. A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 24, 501-505 (2006).
22. Gerschenson, M., Graves, K., Carson, S. D., Wells, R. S. & Pierce, G. B. Regulation of melanoma by the embryonic skin. Proc. Natl Acad. Sci. USA 83, 7307-7310 (1986).
23. Hendrix, M. J. et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Rev. Cancer 7, 246-255 (2007).
24. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999).
25. Hayashi, N. & Cunha, G. R. Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res. 51, 4924-4930 (1991).
26. Tlsty, T. D. & Coussens, L. M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119-150 (2006).
27. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
28. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
29. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24-37 (2006).
30. Ostrand-Rosenberg, S. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 18, 11-18 (2008).
31. Talmadge, J. E., Donkor, M. & Scholar, E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26, 373-400 (2007).
32. Bingle, L., Brown, N. J. & Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002).
33. Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246 (2006).
34. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
35. Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493-12498 (2006).
36. Coussens, L. M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382-1397 (1999).
37. Soucek, L. et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nature Med. 13, 1211-1218 (2007).
38. Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev. Cancer 8, 618-631 (2008).
39. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71-78 (2004).
40. Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266 (2006).
41. Lewis, C. E. & Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612 (2006).
42. Pollard, J. W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 84, 623-630 (2008).
43. Ojalvo, L. S., King, W., Cox, D. & Pollard, J. W. High density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 174, 1048-1064 (2009).
44. Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001). References 33 and 44 used the MMTV-PyMT mammary cancer model to show that macrophage depletion, in a CSF1-deficient background, substantially decreased tumour angiogenesis, invasion and lung metastasis.
45. Hiraoka, K. et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 99, 1595-1602 (2008).
46. Zeisberger, S. M. et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95, 272-281 (2006).
47. Miselis, N. R., Wu, Z. J., Van Rooijen, N. & Kane, A. B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 7, 788-799 (2008).
48. Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818 (2008).
49. Wyckoff, J. et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64, 7022-7029 (2004).
50. Goswami, S. et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65, 5278-5283 (2005).
51. Hernandez, L. et al. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta 1 and CXCL12. Cancer Res. (in the press).
52. Robinson, B. D. et al. Tumor microenvironment of metastasis (TMEM) in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer Res. (in the press). This study found that analysis of invasive carcinoma cells, macrophages and endothelial cells in combination (the TMEM) could be used as a prognostic marker for breast cancer metastasis.
53. + myeloid cells that promote invasion. Nature Genet. 39, 467-475 (2007).
54. Wyckoff, J. B. et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 67, 2649-2656 (2007). References 49 and 54 identified a paracrine loop involving the differential expression of EGF and CSF1, and their receptors, on macrophages and cancer cells, which is an important mediator of cancer invasion and intravasation.
55. Condeelis, J. & Segall, J. E. Intravital imaging of cell movement in tumours. Nature Rev. Cancer 3, 921-930 (2003).
56. Ingman, W. V., Wyckoff, J., Gouon-Evans, V., Condeelis, J. & Pollard, J. W. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev. Dyn. 235, 3222-3229 (2006).
57. Gabrilovich, D. I. et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67, 425; author reply 426 (2007).
58. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166 (2007).
59. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
60. Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. & Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284-290 (2006).
61. Bunt, S. K. et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026 (2007).
62. Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. & Ostrand-Rosenberg, S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179, 977-983 (2007).
63. Sinha, P. et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675 (2008).
64. Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
65. Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biol. 8, 1369-1375 (2006).
66. Hiratsuka, S. et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nature Cell Biol. 10, 1349-1355 (2008). References 65 and 66 identify the inflammatory chemoattractants S100A8 and S100A9 as mediators of myeloid cell recruitment to the pre-metastatic niche in the lung through the serum amyloid A3-TLR4 signalling cascade.
67. + myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (2008). An important paper linking myeloid cell-derived suppressor cells with metastasis.
68. Gordon, S. Alternative activation of macrophages. Nature Rev. Immunol. 3, 23-35 (2003).
69. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
70. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999).
71. Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M. & Marini, F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 15, 730-738 (2008).
72. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007). This study showed that mesenchymal stem cells, when mixed with weakly metastatic breast cancer cells, substantially enhance their metastatic capability, in part through CCL5-CCR5 signalling.
73. 125I-5-iodo-2′-deoxyuridine. J. Natl Cancer Inst. 45, 773-782 (1970).
74. Im, J. H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64, 8613-8619 (2004).
75. Palumbo, J. S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin. Thromb. Hemost. 34, 154-160 (2008).
76. Nieswandt, B., Hafner, M., Echtenacher, B. & Mannel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295-1300 (1999).
77. Palumbo, J. S. et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood 110, 133-141 (2007).
78. Jurasz, P., Alonso-Escolano, D. & Radomski, M. W. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 143, 819-826 (2004).
79. Nash, G. F., Turner, L. F., Scully, M. F. & Kakkar, A. K. Platelets and cancer. Lancet Oncol. 3, 425-430 (2002).
80. Pawelek, J. M. & Chakraborty, A. K. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nature Rev. Cancer 8, 377-386 (2008).
81. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889).
82. Fokas, E., Engenhart-Cabillic, R., Daniilidis, K., Rose, F. & An, H. X. Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev. 26, 705-715 (2007).
83. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev. Cancer 3, 453-458 (2003).
84. Fidler, I. J. & Kripke, M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197, 893-895 (1977).
85. Langley, R. R. & Fidler, I. J. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28, 297-321 (2007).
86. Clark, E. A., Golub, T. R., Lander, E. S. & Hynes, R. O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535 (2000).
87. Nguyen, D. X. & Massague, J. Genetic determinants of cancer metastasis. Nature Rev. Genet. 8, 341-352 (2007).
88. Nguyen, D. X., Bos, P. D. & Massagué, J. Metastasis: from infiltration to colonization. Nature Rev. Cancer (in the press).
89. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). This research revealed that chemokine signalling loops are important in directing tissue-specific metastasis of breast cancer cells.
90. Zlotnik, A. Chemokines in neoplastic progression. Semin. Cancer Biol. 14, 181-185 (2004).
91. Zlotnik, A. New insights on the role of CXCR4 in cancer metastasis. J. Pathol. 215, 211-213 (2008).
92. Li, Y. M. et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6, 459-469 (2004).
93. Marchesi, F. et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68, 9060-9069 (2008).
94. Balkwill, F. Chemokine biology in cancer. Semin. Immunol. 15, 49-55 (2003).
95. + hemangiocytes. Nature Med. 12, 557-567 (2006).
96. Massberg, S. et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrowderived progenitor cells to arterial thrombi in vivo. J. Exp. Med. 203, 1221-1233 (2006).
97. Miles, F. L., Pruitt, F. L., van Golen, K. L. & Cooper, C. R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin. Exp. Metastasis 25, 305-324 (2008).
98. Al-Mehdi, A. B. et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 6, 100-102 (2000).
99. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
100. Wang, H. et al. Tumor cell α3β1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J. Cell Biol. 164, 935-941 (2004).
101. Almholt, K. et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int. J. Cancer 113, 525-532 (2005).
102. Liotta, L. A., Rao, C. N. & Wewer, U. M. Biochemical interactions of tumor cells with the basement membrane. Annu. Rev. Biochem. 55, 1037-1057 (1986).
103. + bone marrow-derived progenitors as key cells in establishing the niche, a process mediated in part through integrin α4 and fibronectin.
104. Rafii, S. & Lyden, D. S100 chemokines mediate bookmarking of premetastatic niches. Nature Cell Biol. 8, 1321-1323 (2006).
105. Wels, J., Kaplan, R. N., Rafii, S. & Lyden, D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 22, 559-574 (2008).
106. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nature Rev. Cancer (in the press).
107. Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006).
108. Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44 (2009).
109. Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300 (2002).
110. McAllister, S. S. et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994-1005 (2008). This paper showed that human breast carcinomas instigate the growth of otherwise indolent cancer cells, through a phenomenon involving BMDC recruitment and osteopontin signalling.
111. Demicheli, R., Retsky, M. W., Hrushesky, W. J. & Baum, M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nature Clin. Pract. Oncol. 4, 699-710 (2007).
112. Demicheli, R., Retsky, M. W., Swartzendruber, D. E. & Bonadonna, G. Proposal for a new model of breast cancer metastatic development. Ann. Oncol. 8, 1075-1080 (1997).
113. Cao, Y. & Xue, L. Angiostatin. Semin. Thromb. Hemost. 30, 83-93 (2004).
114. O'Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996).
115. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S. & Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926-1928 (1999).
116. Stoelcker, B., Hafner, M., Orosz, P., Nieswandt, B. & Mannel, D. N. Role of adhesion molecules and platelets in TNF-induced adhesion of tumor cells to endothelial cells: implications for experimental metastasis. J. Inflamm. 46, 155-167 (1995).
117. Mannel, D. N., Orosz, P., Hafner, M. & Falk, W. Mechanisms involved in metastasis enhanced by inflammatory mediators. Circ. Shock 44, 9-13 (1994).
118. Hafner, M., Orosz, P., Kruger, A. & Mannel, D. N. TNF promotes metastasis by impairing natural killer cell activity. Int. J. Cancer 66, 388-392 (1996).
119. Stathopoulos, G. T. et al. Host nuclear factor-κB activation potentiates lung cancer metastasis. Mol. Cancer Res. 6, 364-371 (2008).
120. Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-107 (2009).
121. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Rev. Cancer 2, 826-835 (2002).
122. Gao, D. et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195-198 (2008).
123. Kerbel, R. S. et al. Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc. Natl Acad. Sci. USA 105, E54; author reply E55 (2008).
124. Purhonen, S. et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105, 6620-6625 (2008).
125. Naumov, G. N., Akslen, L. A. & Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779-1787 (2006).
126. Schwartsburd, P. M. Age-promoted creation of a procancer microenvironment by inflammation: pathogenesis of dyscoordinated feedback control. Mech. Ageing Dev. 125, 581-590 (2004).
127. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001).
128. Campisi, J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522 (2005).
129. Adamson, I. Y., Young, L. & Orr, F. W. Tumor metastasis after hyperoxic injury and repair of the pulmonary endothelium. Lab. Invest. 57, 71-77 (1987).
130. Taranova, A. G. et al. Allergic pulmonary inflammation promotes the recruitment of circulating tumor cells to the lung. Cancer Res. 68, 8582-8589 (2008).
131. Willmann, J. K., van Bruggen, N., Dinkelborg, L. M. & Gambhir, S. S. Molecular imaging in drug development. Nature Rev. Drug Discov. 7, 591-607 (2008).
132. Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7, 513-520 (2005).
133. Gadea, B. B. & Joyce, J. A. Tumour-host interactions: implications for developing anti-cancer therapies. Expert Rev. Mol. Med. 8, 1-32 (2006).
134. Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787 (2006).
135. Shaked, Y. et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263-273 (2008). References 134 and 135 demonstrate that mobilization of endothelial progenitor cells contributes to chemotherapy resistance.
136. + cells, confer refractoriness to anti-VEGFA treatment in cancer models.
137. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev. Cancer 8, 579-591 (2008).
138. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
139. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
140. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nature Rev. Cancer 8, 592-603 (2008).
141. Xian, X. et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116, 642-651 (2006).
142. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174 (2002).
143. Lynch, C. C. & Matrisian, L. M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 70, 561-573 (2002).
144. Mohamed, M. M. & Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer. Nature Rev. Cancer 6, 764-775 (2006).
145. Gocheva, V. & Joyce, J. A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64 (2007).
146. Laufs, S., Schumacher, J. & Allgayer, H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5, 1760-1771 (2006).
147. Masterson, J. & O'Dea, S. Posttranslational truncation of E-cadherin and significance for tumour progression. Cells Tissues Organs 185, 175-179 (2007).
148. Van Damme, J., Struyf, S. & Opdenakker, G. Chemokine-protease interactions in cancer. Semin. Cancer Biol. 14, 201-208 (2004).
149. Mason, S. D. & Joyce, J. A. in Cancer Metastasis: Biologic Basis and Therapeutics (eds Welsh, D. R. & Lyden, D. C.) (Cambridge Univ. Press, Cambridge, UK, 2009) (in the press).
150. Joyce, J. A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453 (2004).
151. Gocheva, V. et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556 (2006). References 150 and 151 show that cysteine cathepsin proteases promote cancer invasion, in part through cleavage of the cell adhesion molecule E-cadherin.
152. Das, S. & Skobe, M. Lymphatic vessel activation in cancer. Ann. NY Acad. Sci. 1131, 235-241 (2008).
153. Saharinen, P., Tammela, T., Karkkainen, M. J. & Alitalo, K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25, 387-395 (2004).
154. Sleeman, J. P. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 157, 55-81 (2000).
155. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448-456 (2004).
156. Klein, C. A. & Holzel, D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5, 1788-1798 (2006).
157. Shiozawa, Y., Havens, A. M., Pienta, K. J. & Taichman, R. S. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22, 941-950 (2008).
158. Klein, C. A. et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360, 683-689 (2002).
159. Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737-7742 (2003).
160. Bussard, K. M., Gay, C. V. & Mastro, A. M. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 27, 41-55 (2008).
161. Mundy, G. R. & Edwards, J. R. The osteoclast - not always guilty. Cell. Metab. 6, 157-159 (2007).
162. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev. Cancer 2, 584-593 (2002).
163. Mundy, G. R. Osteoporosis and inflammation. Nutr. Rev. 65, S147-151 (2007).
164. Leibbrandt, A. & Penninger, J. M. RANK/RANKL: regulators of immune responses and bone physiology. Ann. NY Acad. Sci. 1143, 123-150 (2008).
165. Felix, R., Hofstetter, W., Wetterwald, A., Cecchini, M. G. & Fleisch, H. Role of colony-stimulating factor-1 in bone metabolism. J. Cell Biochem. 55, 340-349 (1994).
166. Kakonen, S. M. & Mundy, G. R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97, 834-839 (2003).
167. Lin, E. Y., Gouon-Evans, V., Nguyen, A. V. & Pollard, J. W. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 7, 147-162 (2002).
168. Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006).
169. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
170. Sohara, Y., Shimada, H. & DeClerck, Y. A. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett. 228, 203-209 (2005).
171. Ara, T. et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 69, 329-337 (2009).
172. Bagnato, A. & Rosano, L. The endothelin axis in cancer. Int. J. Biochem. Cell Biol. 40, 1443-1451 (2008).
173. Valta, M. P. et al. FGF-8 is involved in bone metastasis of prostate cancer. Int. J. Cancer 123, 22-31 (2008).
174. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686 (2004).
175. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958-969 (2008).
176. Lodie, T. A. et al. Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction. Tissue Eng. 8, 739-751 (2002).
177. Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nature Rev. Immunol. 8, 726-736 (2008).
178. Venneri, M. A. et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109, 5276-5285 (2007).
179. Janeway, C., Travers, P., Walport, M. & Shlomchik, M. Immunobiology: the immune system in health and disease 6th edn (Garland Science Publishing, New York, 2005).
180. Ribatti, D., Crivellato, E., Roccaro, A. M., Ria, R. & Vacca, A. Mast cell contribution to angiogenesis related to tumour progression. Clin. Exp. Allergy 34, 1660-1664 (2004).
181. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
182. Bertolini, F. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342-4346 (2003).
183. Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Rev. Cancer 6, 835-845 (2006).
184. Nolan, D. J. et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21, 1546-1558 (2007).
185. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol. 7, 870-879 (2005).
186. Gerhardt, H. & Semb, H. Pericytes: gatekeepers in tumour cell metastasis? J. Mol. Med. 86, 135-144 (2008). References 24 and 186, found that fibroblasts isolated from human prostate or breast cancer dramatically increase tumour cell growth in tissue recombination experiments.
187. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nature Rev. Cancer 6, 392-401 (2006).
188. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
189. de Visser, K. E., Korets, L. V. & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005).
190. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nature Immunol. 9, 503-510 (2008).
191. Waldhauer, I. & Steinle, A. NK cells and cancer immunosurveillance. Oncogene 27, 5932-5943 (2008).
192. + to post-genomics meta-analyses. Curr. Opin. Immunol. 19, 365-372 (2007).